跳至主要内容
临床试验/CTRI/2024/05/067339
CTRI/2024/05/067339尚未招募2 期

A Clinical study on Yakrit vikara w.s.r to Hepatitis and its management with Indigenous drugs

Dr Soumya Sucharita Sarangi1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2024年5月23日最近更新:

试验速览

阶段
2 期
状态
尚未招募
发起方
入组人数
40
试验地点
1
主要终点
To get the billirubin quantity to normal levels and to cure the echogenesity of liver parenchymal cells

研究概览

简要总结

Clinical study on Yakrit vikar wsr to Hepatitis is a Randomised, parallel group multiple arm trial of 3 month duration with Indigenous drugs. The primary outcome of this trial is to cure hepatitis and the secondary outcome is to reduce the elevated liver enzymes and viral load

研究设计

研究类型
Interventional
分配方式
Na
盲法
None

入排标准

年龄范围
18.00 Year(s) 至 65.00 Year(s)(—)
性别
All

入选标准

  • Drug induced hepatitis Hepatitis A & E Alcohol induced hepatitis.

排除标准

  • Hepatitis with other metabolic disorders Lactating & pregnant women auto-immune hepatitis Hepatitis B,C,D.

结局指标

主要结局

To get the billirubin quantity to normal levels and to cure the echogenesity of liver parenchymal cells

时间窗: 3 months

次要结局

  • To reduce the elevated liver enzymes and viral load(3 months)

研究者

发起方
Dr Soumya Sucharita Sarangi
申办方类型
Other [self]
责任方
Principal Investigator
主要研究者

Dr Soumya Sucharita Sarangi

Gopabandhu Ayurveda Mahavidyalaya

研究点 (1)

Loading locations...

相似试验